Glenmark Pharma completes Phase-I of GBR 1302; ends lower
The company announced that its subsidiary GPSA announces the completion of Phase 1 supporting studies and the submission of a clinical trial application to the Paul-Ehrlich Institute in Germany with a novel clinical development candidate, GBR 1302. GBR 1302 is a HER2xCD3 bi-specific antibody based on Glenmark’s proprietary BEAT platform.